Literature DB >> 10654111

The role of immune function in schizophrenia: an overview.

N Müller1, M Riedel, M Ackenheil, M J Schwarz.   

Abstract

Immune alterations in schizophrenia have been described for decades. However, modern immunological methods and new insights into the highly developed and functionally differentiated immune system allows an integrative view of both, the older and also recent findings of immunological abnormalities in schizophrenia. Both, the unspecific and the specific arm of the immune system seem to be involved in the dysfunction of the immune system in schizophrenia. The unspecific "innate" immune system shows signs of an overactivation in unmedicated schizophrenic patients, as increased monocytes and gamma delta-cells point to. Increased levels of Interleukin-6 (IL-6) and the activation of the IL-6 system in schizophrenia might also be the result of the activation of monocytes/macrophages. On the contrary, several parameters of the specific cellular immune system are blunted, e.g. the decreased T-helper-1 (TH-1) related immune parameters in schizophrenic patients both, in vitro and in vivo. It seems that a TH-1-TH-2 imbalance with a shift to the TH-2 system is associated with schizophrenia. During antipsychotic therapy with neuroleptics, the specific TH-1 related immune answer becomes activated, but also the B-cell system and the antibody production increases.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10654111     DOI: 10.1007/pl00014187

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  23 in total

1.  Circulating immune complexes in blood of patients with positive family history of schizophrenia.

Authors:  S Hakobyan; G Avetisyan; A Boyajyan; S Torosyan; G Khachatryan; S Tatevosyan
Journal:  Dokl Biochem Biophys       Date:  2001 Sep-Oct       Impact factor: 0.788

2.  The impact of clinical heterogeneity in schizophrenia on genomic analyses.

Authors:  Sherri G Liang; Tiffany A Greenwood
Journal:  Schizophr Res       Date:  2014-12-10       Impact factor: 4.939

3.  Differential age- and disease-related effects on the expression of genes related to the arachidonic acid signaling pathway in schizophrenia.

Authors:  Bin Tang; Cristina Capitao; Brian Dean; Elizabeth A Thomas
Journal:  Psychiatry Res       Date:  2012-03-06       Impact factor: 3.222

4.  Functional polymorphism in the interleukin-6 and interleukin-10 genes in patients with paranoid schizophrenia--a case-control study.

Authors:  Monika Paul-Samojedny; Malgorzata Kowalczyk; Renata Suchanek; Aleksander Owczarek; Anna Fila-Danilow; Aleksandra Szczygiel; Jan Kowalski
Journal:  J Mol Neurosci       Date:  2010-09       Impact factor: 3.444

Review 5.  Th17 pathway-mediated immunopathogenesis of schizophrenia: mechanisms and implications.

Authors:  Monojit Debnath; Michael Berk
Journal:  Schizophr Bull       Date:  2014-04-07       Impact factor: 9.306

6.  The effects of Ginkgo biloba extract added to haloperidol on peripheral T cell subsets in drug-free schizophrenia: a double-blind, placebo-controlled trial.

Authors:  Xiang Yang Zhang; Dong Feng Zhou; Lian Yuan Cao; Gui Ying Wu
Journal:  Psychopharmacology (Berl)       Date:  2006-08-12       Impact factor: 4.530

7.  Superoxide dismutase and cytokines in chronic patients with schizophrenia: association with psychopathology and response to antipsychotics.

Authors:  Xiang Yang Zhang; Dong Feng Zhou; Ling Yan Qi; Song Chen; Lian Yuan Cao; Da Chun Chen; Mei Hong Xiu; Fan Wang; Gui Ying Wu; Lin Lu; Therese A Kosten; Thomas R Kosten
Journal:  Psychopharmacology (Berl)       Date:  2009-01-13       Impact factor: 4.530

8.  Association of SNPs and haplotypes in APOL1, 2 and 4 with schizophrenia.

Authors:  Sakae Takahashi; Yu-hu Cui; Yong-hua Han; Jesen A Fagerness; Brian Galloway; Yu-cun Shen; Takuya Kojima; Makoto Uchiyama; Stephen V Faraone; Ming T Tsuang
Journal:  Schizophr Res       Date:  2008-07-16       Impact factor: 4.939

9.  Lower serum cytokine levels in smokers than nonsmokers with chronic schizophrenia on long-term treatment with antipsychotics.

Authors:  Xiang Yang Zhang; Lian Yuan Cao; Cai Song; Gui Ying Wu; Da Chun Chen; Ling Yan Qi; Fan Wang; Mei Hong Xiu; Song Chen; Yingyang Zhang; Lin Lu; Therese A Kosten; Thomas R Kosten
Journal:  Psychopharmacology (Berl)       Date:  2008-08-22       Impact factor: 4.530

Review 10.  Markers of vulnerability in schizophrenia.

Authors:  Maria Ladea; Dan Prelipceanu
Journal:  J Med Life       Date:  2009 Apr-Jun
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.